3TR SIGNED
Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions
Total Cost €
0EC-Contrib. €
0Partnership
0Views
03TR project word cloud
Explore the words cloud of the 3TR project. It provides you a very rough idea of what is the project "3TR" about.
Project "3TR" data sheet
The following table provides information about the project.
| Coordinator |
FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Total cost | 80˙803˙177 € |
| EC max contribution | 40˙273˙191 € (50%) |
| Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
| Code Call | H2020-JTI-IMI2-2018-14-two-stage |
| Funding Scheme | IMI2-RIA |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-09-01 to 2026-08-31 |
Partnership
Take a look of project's partnership.
Map
Project objective
3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "3TR" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "3TR" are provided by the European Opendata Portal: CORDIS opendata.